Not Tagged
zymeworks
['solid tumor', 'zymeworks']
cd3-bispecific t cell engager therapies have exhibited clinical utility against hematological malignancies, but successes in solid tumor indications have been limited. tritce cpi antibodies have the potential to improve t cell responses in immunosuppressed solid tumors. #aacr23 
We’re on a mission to bring patients home to their loved ones, disease free.